ArticleCureus2025
Breakthrough Seizures in Children Receiving Valproate Therapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Breakthrough seizures in children diagnosed with epilepsy pose a significant clinical challenge. Though valproate is effective in managing seizures, a subset of patients can still experience breakthrough seizures. It can cause increased morbidity, reduce the quality of life, and increase anxiety among parents. There is insufficient data in the Indian population regarding the cause of breakthrough seizures and their association with serum valproate levels; hence, we carried out this study. Objective Primary Objective To study the clinical profile and drug levels in children presenting with breakthrough seizures while receiving valproate therapy. Secondary Objective To find out the association of the clinical, demographic, and etiological profile of breakthrough seizures with valproate levels. Methods A group of 100 children, 2-12 years old, receiving valproate therapy and presenting to the hospital within 24 hours of a breakthrough seizure were studied. Clinical and demographic profiles were recorded. Valproate levels were estimated using recombinant DNA technology using an autoanalyzer (reference level 50-100 mcg/ml). Phenytoin levels were estimated in 10 children receiving dual therapy (reference level 10-20 mcg/mL). Results The mean age was 81.6±31.9 months (59 M, 41 F). The mean dose of valproate was 24.8±8.4 mg. Syrup formulation was used in 73 and tablets in 27. Non-compliance was observed in 19, and fever was identified as a possible precipitating factor in 18. Compliance was not affected by age, sex, socioeconomic status, education of parents, or type of seizure (p > 0.05). Valproate levels were below the reference range in 44, within the reference range in 47, and above the reference range in 9. There was no statistically significant association between valproate levels (therapeutic or subtherapeutic) and age, sex, socioeconomic status, parental education, seizure type, or the presence of precipitating factors (p > 0.05). Similarly, mean valproate levels were also not affected by these factors. The levels did not vary with drug formulations. Conclusion Breakthrough seizures in children on valproate therapy were not related to valproate levels. Valproate levels were not affected by clinical or demographic profile, drug formulation, change in formulation, compliance, etc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.